gms | German Medical Science

124. Kongress der Deutschen Gesellschaft für Chirurgie

Deutsche Gesellschaft für Chirurgie

01. - 04.05.2007, München

Local recurrence model of malignant pleural mesothelioma established in a small animal

Meeting Abstract

  • corresponding author I. Opitz - Klinik für Thoraxchirurgie, Universitätsklinik Zürich, Schweiz
  • D. Lardinois - Klinik für Thoraxchirurgie, Universitätsklinik Zürich, Schweiz
  • S. Hillinger - Klinik für Thoraxchirurgie, Universitätsklinik Zürich, Schweiz
  • P. Vogt - Klinik für Patholgie, Universitätsklinik Zürich, Schweiz
  • S. Arni - Klinik für Thoraxchirurgie, Universitätsklinik Zürich, Schweiz
  • W. Weder - Klinik für Thoraxchirurgie, Universitätsklinik Zürich, Schweiz

Deutsche Gesellschaft für Chirurgie. 124. Kongress der Deutschen Gesellschaft für Chirurgie. München, 01.-04.05.2007. Düsseldorf: German Medical Science GMS Publishing House; 2007. Doc07dgch7533

The electronic version of this article is the complete one and can be found online at:

Published: October 1, 2007

© 2007 Opitz et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Introduction: Local recurrence remains a major problem in the treatment of malignant pleural mesothelioma (MPM). The aim of the underlying study was to establish a standardised local recurrence model in rats which enables us to study different local adjuvant therapies.

Materials and methods: Under general anaesthesia, a tumour cell suspension of 50 μl containing 1x106 rat malignant mesothelioma cell (II-45), established from experimentally induced mesothelioma in Fisher 344 rats exposed to asbestos, was inoculated subpleurally via a left-sided thoracotomy. The tumour size was assessed 6 days later and the tumour nodule completely resected. Assessment of recurrence at the resection site was performed in the first group after 10 days (n=5) and in a second group after 6 days (n=5). The recurrent nodule was histopathologically confirmed.In a second series this new recurrence model was evaluated for treatment effect of the adjuvant intrapleural application of cisplatin in a concentration of 100 mg2/kg BW or cisplatin in the same concentration combined with the fibrin-based sealant Vivostat® after left sided pneumonectomy. The primary endpoint was the thickness of the tumour evaluated by a blinded pathologist in the HE-section performed at the thickest diameter of the recurrence.

Results: 6 days after tumour cell inoculation all animals presented a standardised tumour nodule at the injection site of a mean diameter of 5.125 mm (± 0.8). Evaluation of the recurrence after 10 days (n=5) showed that there was a relapse directly at the resection site, but further tumour nodules on the same and the contralateral chest wall were found during autopsy and were histologically confirmed. The animals sacrificed 6 days after resection of the tumour nodule (n=5) showed a local recurrence only at the resection site with no macroscopic or microscopic evidence of other tumour. Resection of the tumour nodule plus pneumonectomy combined with intrapleural application of both agents lead to significant reduction of the recurrence.

Discussion: With this new recurrence model for investigation of MPM in rats, we were able to investigate new adjuvant intrapleural therapies after pleuropneumonectomy. The intrapleural application of cisplatin and Cisplatin-Vivostat® the extent of local recurrence.